BI Inks Second Obesity Pact With Denmark’s Gubra
Executive Summary
The German group has signed a second deal with Gubra to develop poly-agonist peptides for obesity that could be worth up to €240m.
You may also be interested in...
Boehringer Ingelheim, Gubra Enter Third Obesity Deal
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Boehringer Adds Yuhan’s First-In-Class Dual Agonist To NASH Portfolio
Yuhan reaches $870m NASH licensing-out deal with Boehringer, touting its competitiveness in the space after earlier alliance with Gilead. The collaboration for first-in-class GLP-1/FGF21 dual agonist is poised to beef up German firm's R&D expertise in cardiometabolic disease.
Deal Watch: Vertex Expands Gene-Editing Efforts With A Pair Of Deals
CF-focused Vertex will buy Exonics and expand a collaboration with CRISPR Therapeutics, with plans to develop therapies for DMD and myotonic dystrophy type 1. Merck acquires TGFβ-focused Tilos, while Achaogen offloads most of its assets at auction.